



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #21-19) 06/25/2019
Pernix Therapeutics Hldgs, Inc. (PTXTQ)

Notice has been received that the above Company's Third Amended Joint Plan of Liquidation became effective on 06/24/2019. Pursuant to the plan, all equity shares shall be cancelled and deemed null and void on the Effective Date, and holders thereof shall not receive any Distribution on any account of such existing Pernix Therapeutics Hldgs., Inc. interests. Please consult the company's bankruptcy filings for thorough details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

¹ See e.g., *In re: Pernix Sleep, Inc., et al.*, Debtors. Chapter 11 Case No. 19-10323 Third Amended Joint Plan of Liquidation of Pernix Sleep, Inc. and its Affiliated Debtors and Debtors In Possession Pursuant to Chapter 11 Of the Bankruptcy Code.